Michael Reader Selected Research

Neoplasms (Cancer)

10/2021	ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
1/2021	Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
8/2015	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP.
9/2011	Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Reader Research Topics

Disease

4	Neoplasms (Cancer) 10/2021 - 09/2011
1	Melanoma (Melanoma, Malignant) 01/2018

Drug/Important Bio-Agent (IBA)

2	ASTX029IBA 10/2021 - 01/2021
1	Ribosomal Protein S6 Kinases (S6 Kinase)IBA 10/2021
1	Mitogen-Activated Protein KinasesIBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)IBA 01/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2018
1	Inhibitor of Apoptosis ProteinsIBA 08/2015
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 09/2011
1	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 09/2011